Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice
- PMID: 25062610
- DOI: 10.3920/BM2014.0014
Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice
Abstract
Alterations of the gut microbiota and mucosal barrier are linked with metabolic diseases. Our aim was to investigate the potential benefit of the potential probiotic Bifidobacterium animalis ssp. lactis 420 in reducing high-fat diet-induced body weight gain and diabetes in mice. In the obesity model, C57Bl/6J mice were fed a high-fat diet (60 energy %) for 12 weeks, and gavaged daily with B. lactis 420 (109 cfu) or vehicle. In the diabetes model, mice were fed a high-fat, ketogenic diet (72 energy % fat) for 4 weeks, with a 6-week subsequent treatment with B. lactis 420 (108-1010 cfu/day) or vehicle, after which they were analysed for body composition. We also analysed glucose tolerance, plasma lipopolysaccharide and target tissue inflammation using only one of the B. lactis 420 groups (109 cfu/day). Intestinal bacterial translocation and adhesion were analysed in a separate experiment using an Escherichia coli gavage. Body fat mass was increased in both obese (10.7 ± 0.8 g (mean ± standard error of mean) vs. 1.86 ± 0.21 g, P<0.001) and diabetic mice (3.01 ± 0.4 g vs. 1.14 ± 0.15 g, P<0.001) compared to healthy controls. Treatment with B. lactis 420 significantly decreased fat mass in obese (7.83 ± 0.67 g, P=0.007 compared to obese with vehicle) and diabetic mice (1.89 ± 0.16 g, P=0.02 for highest dose). This was reflected as reduced weight gain and improved glucose tolerance. Furthermore, B. lactis 420 decreased plasma lipopolysaccharide levels (P<0.001), liver inflammation (P=0.04), and E. coli adhesion in the distal gut (P<0.05). In conclusion, B. lactis 420 reduces fat mass and glucose intolerance in both obese and diabetic mice. Reduced intestinal mucosal adherence and plasma lipopolysaccharide suggest a mechanism related to reduced translocation of gut microbes.
Keywords: diabetes; intestinal permeability; mice; obesity; probiotics.
Similar articles
-
Bifidobacterium animalis subsp. lactis 420 for Metabolic Health: Review of the Research.Nutrients. 2020 Mar 25;12(4):892. doi: 10.3390/nu12040892. Nutrients. 2020. PMID: 32218248 Free PMC article. Review.
-
Glucosamine enhances body weight gain and reduces insulin response in mice fed chow diet but mitigates obesity, insulin resistance and impaired glucose tolerance in mice high-fat diet.Metabolism. 2015 Mar;64(3):368-79. doi: 10.1016/j.metabol.2014.11.005. Epub 2014 Nov 20. Metabolism. 2015. PMID: 25516476
-
Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats.Obesity (Silver Spring). 2014 Mar;22(3):763-71. doi: 10.1002/oby.20632. Epub 2013 Oct 17. Obesity (Silver Spring). 2014. PMID: 24124012
-
Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity.Gut. 2013 Feb;62(2):220-6. doi: 10.1136/gutjnl-2011-300705. Epub 2012 Feb 16. Gut. 2013. PMID: 22345653
-
THE EFFECT OF PROBIOTIC FERMENTED MILK THAT INCLUDES BIFIDOBACTERIUM LACTIS CNCM I-2494 ON THE REDUCTION OF GASTROINTESTINAL DISCOMFORT AND SYMPTOMS IN ADULTS: A NARRATIVE REVIEW.Nutr Hosp. 2015 Aug 1;32(2):501-9. doi: 10.3305/nh.2015.32.2.9232. Nutr Hosp. 2015. PMID: 26268077 Review.
Cited by
-
Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial.Nutrients. 2020 Oct 13;12(10):3123. doi: 10.3390/nu12103123. Nutrients. 2020. PMID: 33066107 Free PMC article. Clinical Trial.
-
Serological Biomarkers and Diversion Colitis: Changes after Stimulation with Probiotics.Biomolecules. 2021 May 2;11(5):684. doi: 10.3390/biom11050684. Biomolecules. 2021. PMID: 34063276 Free PMC article. Clinical Trial.
-
Lactobacillus gasseri SBT2055 inhibits adipose tissue inflammation and intestinal permeability in mice fed a high-fat diet.J Nutr Sci. 2016 May 30;5:e23. doi: 10.1017/jns.2016.12. eCollection 2016. J Nutr Sci. 2016. PMID: 27293560 Free PMC article.
-
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020 May;158(6):1597-1610.e7. doi: 10.1053/j.gastro.2020.01.031. Epub 2020 Jan 25. Gastroenterology. 2020. PMID: 31987796 Free PMC article. Clinical Trial.
-
Bifidobacterium animalis subsp. lactis 420 for Metabolic Health: Review of the Research.Nutrients. 2020 Mar 25;12(4):892. doi: 10.3390/nu12040892. Nutrients. 2020. PMID: 32218248 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical